WO2023121614A2 - Greffon vasculaire naturel, elastique et bioactif - Google Patents
Greffon vasculaire naturel, elastique et bioactif Download PDFInfo
- Publication number
- WO2023121614A2 WO2023121614A2 PCT/TR2022/051234 TR2022051234W WO2023121614A2 WO 2023121614 A2 WO2023121614 A2 WO 2023121614A2 TR 2022051234 W TR2022051234 W TR 2022051234W WO 2023121614 A2 WO2023121614 A2 WO 2023121614A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vascular graft
- hyaluronic acid
- bio
- alginate
- ink
- Prior art date
Links
- 230000002792 vascular Effects 0.000 title claims abstract description 64
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 13
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 28
- 210000003462 vein Anatomy 0.000 claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 238000007631 vascular surgery Methods 0.000 claims abstract description 8
- 230000007850 degeneration Effects 0.000 claims abstract description 7
- 230000001771 impaired effect Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 39
- 229940072056 alginate Drugs 0.000 claims description 27
- 229920000615 alginic acid Polymers 0.000 claims description 27
- 235000010443 alginic acid Nutrition 0.000 claims description 27
- 229920002674 hyaluronan Polymers 0.000 claims description 27
- 229960003160 hyaluronic acid Drugs 0.000 claims description 27
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 26
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 26
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 23
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 14
- 239000000499 gel Substances 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 13
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Substances OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 10
- -1 tyramine compound Chemical class 0.000 claims description 10
- 229960003732 tyramine Drugs 0.000 claims description 8
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 210000005003 heart tissue Anatomy 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 239000012620 biological material Substances 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 4
- 238000004132 cross linking Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- WNFHGZLVUQBPMA-JSCKKFHOSA-M Sodium glucuronate Chemical compound [Na+].O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C([O-])=O WNFHGZLVUQBPMA-JSCKKFHOSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3625—Vascular tissue, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y10/00—Processes of additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
Definitions
- the invention relates to a natural, elastic, and bioactive vascular graft for use in the technical field of vascular surgery to repair or bypass veins with occlusion, impaired integrity, or aneurysmal degeneration, comprising decellularized extracellular matrices and biomaterials as raw materials, and the production of this vascular graft and the use of the said vascular graft.
- prosthetic grafts which are used in vascular surgery to repair or bypass the veins with occlusion, impaired integrity, or aneurysmal degeneration. With the experience of vascular surgery in its first years of development, its ideal graft characteristics were determined. The success of the clinical use of vascular grafts depends upon the physical properties of these prostheses. Grafts are classified as synthetic and natural according to their structure and composition. When choosing grafts, factors such as patency rates, suitability for the surgery to be performed and the patient, absence of complications, and high cost should be taken into consideration.
- Ischemic diseases such as atherosclerotic cardiovascular disease remain one of the leading causes of mortality and morbidity worldwide.
- Demand for vascular ducts is increasing to solve vascular occlusion problems.
- Bypass surgery in which an artificial or autologous tube is inoculated into an existing vein to restore blood flow around the occluded or damaged part of the vein, is one of the most common treatments for such diseases.
- Synthetic grafts were developed with tissue engineering approaches to replace occluded arterial veins, but these synthetic vascular grafts could not significantly reduce overall mortality and morbidity.
- the invention with patent number EP09887998 relates to tissue decellularization and especially a method for treating tissues such as heart valves, tendons, and ligaments, in such a way as to decellularize them and thereby limit mineralization and/or immunoreactivity upon in vivo administration.
- the invention with patent number W02007048831 A2 relates to the addition of discontinuous Extra Cellular Matrix (abbreviated as ECM) regions to a biodegradable scaffold.
- ECM Extra Cellular Matrix
- the optimal amount of separate ECM material for each application is described, and this concentration is evenly distributed within the dressing, thus avoiding unnecessary high ECM concentrations.
- the porous structure of the base material provides the cells with a structure for growth.
- the present invention relates to the acquisition of natural vascular grafts which eliminates the disadvantages in the related technical field and offers additional technical solutions and advantages for the related technical field.
- the object of the invention is to provide vascular grafts obtained from completely natural components.
- Another object of the invention is to provide a vascular graft with elastic and bioactive properties.
- the invention relates to obtaining natural vascular grafts from regenerative biomaterials.
- the invention is to present a new method for obtaining the natural vascular graft.
- the invention relates to a natural, bioactive, and elastic vascular graft for use in vascular surgery to repair or bypass the veins with occlusion, impaired integrity, or aneurysmal degeneration, comprising
- Hyaluronic acid to provide elasticity properties
- Decellularized extracellular matrix to provide bioactivity and functionality.
- a preferred embodiment of the invention is that the alginate component is cross-linked with the calcium chloride compound.
- a preferred embodiment of the invention is that hyaluronic acid is polymerized with the tyramine compound.
- a preferred embodiment of the invention is that the tyramine-hyaluronic acid compound is cross-linked with the hydrogen peroxide compound.
- a preferred embodiment of the invention is that it comprises a decellularized extracellular matrix obtained from bone, cartilage, nerve, muscle, skin, cardiac tissue, and aortic vein tissue.
- a preferred embodiment of the invention is the aortic vein tissues of the decellularized extracellular matrix.
- a preferred embodiment of the invention is that the decellularized extracellular matrix obtained from the aortic tissues is cross-linked.
- the invention also relates to the production of the characterized natural vascular graft.
- the said production method is characterized in that it comprises the steps of i) obtaining bio-ink containing hyaluronic acid, alginate, and decellularized extracellular matrix as components and ii) producing the resulting bio-ink in tubular form by means of a 3D printer.
- it comprises the mixture of alginate:hyaluronic acid:decellularized extracellular matrix in the ratio of 1 .5:1 :1 by weight in the said bio-ink.
- the mixture of alginate:hyaluronic acid:decellularized extracellular matrix is incubated at temperatures of 36-37°C before the bio-ink is obtained.
- the incubation process takes at least 45 minutes.
- the production method of the invention includes the following process steps; i. Preparing alginate and tyramine-hyaluronic acid solutions, ii. Adding aortic gels to the solution obtained in step i), iii. Incubating the mixture obtained in step ii) and obtaining the bio-ink, iv. Placing the mixture incubated in step iii) in the syringe to be used in the 3D printer as bio-ink, v. Producing the bio-ink obtained in the process step iv) in the tubular form in a 3D printer.
- the number of coating of the 3D printer is 20 layers.
- the extruder width of the 3D printer is in the range of 0.2 to 0.4 mm.
- the thickness of the product obtained by the application of the 3D printer is in the range of 10 to 20 mm.
- the speed of the 3D printer is in the range of 8 to 12 mm/second.
- the pressure of the 3D printer is in the range of 50 to 60 kPa.
- the subject of the invention relates to a natural, elastic, and bioactive vascular graft for use in the technical field of vascular surgery to repair or bypass veins with occlusion, impaired integrity, or aneurysmal degeneration, comprising decellularized cellular matrices and biomaterials as raw materials, and it is explained with examples that do not have any limiting effect only for a better understanding of the subject.
- the vascular graft of the invention is a composite material containing natural biomaterials.
- the said composite material contains regenerative and biocompatible biomaterials. In this way, natural vascular grafts with highly elastic and mechanical strength and bioactive properties can be obtained.
- the vascular graft of the invention contains an alginate component.
- Alginate' 1 is a polysaccharide that is hydrophilic and is widely dispersed in the cell walls of brown algae, which when hydrated form a viscous gum.
- the alginate component is included in the vascular graft of the invention due to its positive properties such as being biocompatible, hydrophilic, and cost-effective, being biologically absorbable, not being immunogenic, and ease of gelling.
- the alginate component has the appropriate mechanical strength for sewing.
- the alginate compound in the vascular graft of the invention can preferably be cross-linked by means of cross-linking solutions. With cross-linking, alginate can reach high mechanical strength values. Calcium chloride ionic solution is used for cross-linking of the alginate compound.
- the vascular graft of the invention contains hyaluronic acid as a component.
- Hyaluronic acid is a linear polysaccharide consisting of sodium D-glucuronate and N-acetyl- D-glucosamine and having recurrent disaccharide units.
- Naturally occurring glycosaminoglycan is a component of the skin, joint fluid, and subcutaneous tissues.
- Hyaluronic acid can be metabolically excreted from the body and plays a role in protecting cells and maintaining the structural integrity of tissues.
- Hyaluronic acid is used in the art in various material designs to prevent tissue adhesion after surgery.
- Hyaluronic acid is biocompatible, bio-absorbable/non-immunogenic, polyanionic, hydrophilic, and anti-fibrotic.
- the hyaluronic acid component is present in the inventive vascular graft as a hyaluronic acid- tyramine biomaterial, preferably obtained by polymerization with tyramine.
- Tyramine is HTA polymerized by oxidative bonding reaction of hydrogen peroxide (H2O2) and horseradish peroxidase (HRP) compound and HTA hydrogel is formed.
- the hyaluronic acid-tyramine bio-component provides high elasticity for the vascular graft according to the invention.
- the vascular graft of the invention is subjected to cross-linking processes with hyaluronic acid, preferably cross-linking compounds.
- the hydrogen peroxide compound is used as the cross-linking component.
- the vascular graft of the invention contains an aortic extracellular matrix that is free of cells.
- the decellularized extracellular matrix (ECM) provides bioactivity and functionality for the vascular graft of the invention. It is obtained from tissues, not tumorigenic.
- the inventors have provided the extracellular matrix component that has been decellularized by decellularization of the aortic vein.
- the process of decellularizing the said aortic vein comprises the following steps:
- the aortic vein obtained is first mechanically separated, Undesirable residues such as fat, blood, etc. are removed from the mechanically separated aortic vein and thoroughly washed with phosphate buffer (PBS),
- PBS phosphate buffer
- the aortic artery is cut into small pieces so that it can be easily separated from its cells
- DMEM Dulbecco's Modified Eagle Medium
- aortic samples are rinsed again with ultrapure water and aortic gels are obtained.
- the aortic vein is preferably divided into 2*4 cm pieces. In this way, the surface area of the aortic samples is increased and faster and more precise reactions are achieved for the aortic gel to be obtained.
- the said trizma hydrochloride preferably has a concentration of 5 to 15 millimoles (mM).
- the said EDTA solution is a solution of 0.05% to 0.2% by weight.
- the aortic samples in the said trizma hydrochloride-EDTA solution are subjected to mixing in a magnetic stirrer for at least 1 hour.
- the said stirring is preferably carried out at room temperature.
- the concentration of the said dimethylsulfoxide compound is in the range of 0.5 M to 2 M.
- the sodium dodecyl sulfate solution contains 1% by weight of the dimethylsulfoxide compound.
- the said magnetic stirring is carried out for at least 3 hours. Magnetic stirring is carried out at room temperature.
- Dulbecco's Modified Eagle Medium (abbreviated as DMEM) solution contains 3% by weight of antibiotic/antimycotic components. Preferably, the DMEM solution is changed every 12 hours.
- Aortic gels obtained with the information given in the invention can be cross-linked if preferred. The aortic gels are incubated for cross-linking and the temperature of the said incubation is carried out at 36-37°C.
- the vascular graft of the invention comprises decellularized aortic gels, hyaluronic acid, and alginate components obtained with the information provided in the invention.
- the vascular graft of the invention comprises decellularized aortic gels, hyaluronic acid- tyramine, and alginate components obtained with the information provided in the invention.
- the vascular graft of the invention comprises decellularized aortic gels, cross-linked hyaluronic acid-tyramine, and cross-linked alginate components obtained with the information provided in the invention.
- the invention also provides a method for the production of vascular grafts.
- the vascular graft comprises the process steps of producing the components in the form of grafts by means of a 3D printer with the bio-ink obtained after obtaining the components as bio-ink.
- the following process steps are performed for the production of the vascular graft according to the invention; i. Preparing alginate and tyramine-hyaluronic acid solutions, ii. Adding aortic gels to the solution obtained in step i), iii. Incubating the mixture obtained in step ii), iv. Placing the mixture incubated in step iii) in the syringe to be used in the 3D printer as bio-ink, v. Producing the bio-ink obtained in the process step iv) in the tubular form in a 3D printer.
- the alginate obtained in process step ii) is in the form of 1.5:1 :1 by weight of the mixture of tyramine-hyaluronic acid:aortic gel.
- the incubation process is carried out at a temperature of 36-37°C in process step iii). Preferably, the incubation is carried out for 40 to 60 minutes.
- the vascular graft of the invention can be cross-linked using cross-links if the vascular graft is preferred in the tubular form obtained by applying the process steps of the production method.
- Solutions containing one or both H2O2 and/or CaCh solutions are used as crosslinkers in the invention.
- Solutions preferably containing H2O2 and CaCh compounds together are used as cross-linkers in the invention.
- H2O2:CaCl2 solution prepared with 1 :10 (v:v) value by volume is used as a crosslinker.
- the cross-linking process is carried out for at least 2 hours.
- the vascular graft of the invention is preferably subjected to UV-sterilization processes to increase its optical permeability after cross-linking.
- the raw materials of the vascular graft of the invention can be obtained easily and their costs are quite low.
- the unit production cost of the final product vascular graft to be obtained in this way is quite low.
- the vascular graft of the invention contains completely natural components.
- Vascular graft obtained from natural components is not tumorigenic, supports angiogenesis, and can be used as both gel and tissue scaffolding.
- the vascular graft of the invention can be biocompatible and bioactive thanks to the natural components it contains.
- the vascular graft of the invention has high flexibility.
- the vascular graft obtained is unbreakable, unbreakable thanks to its elastic structure, and is a candidate for use instead of natural vascular tissue.
- the vascular graft of the invention has mechanical strength and elasticity at the level that can be used instead of the vein at the same time.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Manufacturing & Machinery (AREA)
- Materials Engineering (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
Abstract
L'invention concerne un greffon vasculaire naturel, élastique et bioactif destiné à être utilisé dans le domaine technique de la chirurgie vasculaire pour réparer ou contourner des veines avec occlusion, intégrité altérée, ou dégénérescence anévrismale, comprenant des matrices extracellulaires décellularisées et des biomatériaux en tant que matières premières, ainsi que la production de ce greffon vasculaire et l'utilisation dudit greffon vasculaire.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2021/020673A TR2021020673A2 (tr) | 2021-12-22 | 2021-12-22 | Doğal, elasti̇k, bi̇yoakti̇f özelli̇klerde bi̇r damar grefti̇ |
TR2021/020673 | 2021-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023121614A2 true WO2023121614A2 (fr) | 2023-06-29 |
WO2023121614A3 WO2023121614A3 (fr) | 2023-08-24 |
Family
ID=85116856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2022/051234 WO2023121614A2 (fr) | 2021-12-22 | 2022-11-03 | Greffon vasculaire naturel, elastique et bioactif |
Country Status (2)
Country | Link |
---|---|
TR (1) | TR2021020673A2 (fr) |
WO (1) | WO2023121614A2 (fr) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102908207B (zh) * | 2012-10-30 | 2015-04-22 | 南通大学 | 生物打印技术制备的组织工程神经移植物及其制备方法 |
WO2016033337A1 (fr) * | 2014-08-27 | 2016-03-03 | The Cleveland Clinic Foundation | Greffe de tissu biocompatible |
JP7210584B2 (ja) * | 2017-11-29 | 2023-01-23 | オールジャン バイオセラピューティクス エス.アー. | 滅菌積層造形システム |
KR102253724B1 (ko) * | 2019-11-26 | 2021-05-20 | 주식회사 티앤알바이오팹 | 회전형 3d 프린팅 조형판 및 이를 포함하는 3d 프린터 |
WO2021177503A1 (fr) * | 2020-03-06 | 2021-09-10 | 주식회사 엘앤씨바이오 | Composition utilisant une encre biologique à base de composant cartilagineux pour construire une structure à des fins de traitement de microtie, et procédé de préparation associé |
-
2021
- 2021-12-22 TR TR2021/020673A patent/TR2021020673A2/tr unknown
-
2022
- 2022-11-03 WO PCT/TR2022/051234 patent/WO2023121614A2/fr unknown
Also Published As
Publication number | Publication date |
---|---|
TR2021020673A2 (tr) | 2022-01-21 |
WO2023121614A3 (fr) | 2023-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10265436B2 (en) | Immobilized bioactive hydrogel matrices as surface coatings | |
US5476666A (en) | Glycosaminoglycan-synthetic polymer conjugates | |
Panduranga Rao | Recent developments of collagen-based materials for medical applications and drug delivery systems | |
US5523348A (en) | Method of preparing collagen-polymer conjugates | |
US5446091A (en) | Collagen-polymer conjugates containing an ether linkage | |
US5304595A (en) | Collagen-polymer conjugates | |
JP2000502380A (ja) | 架橋ポリマー組成物およびその使用方法 | |
JPS6192671A (ja) | 化学的物質 | |
JPWO2003092759A1 (ja) | 多孔質複合材料の製造方法 | |
EP1609493B1 (fr) | Utilisation de prothèses tridimensionnelles contenant des dérives de l'acide hyaluronique | |
CN107397980A (zh) | 一种组织修复膜涂覆用防粘连组合物及其使用方法 | |
CN113476657A (zh) | 一种用于软骨组织工程的胶原基水凝胶及其制备方法 | |
JP4895461B2 (ja) | 骨修復におけるビブリオ・ディアボリカス種によって放出されたポリサッカライドの用途 | |
WO2023121614A2 (fr) | Greffon vasculaire naturel, elastique et bioactif | |
CN115137883B (zh) | 一种仿生复合矿化支架及其制备方法 | |
Chandy et al. | The development of porous alginate/elastin/PEG composite matrix for cardiovascular engineering | |
Amudeswari et al. | Short‐term biocompatibility studies of hydrogel‐grafted collagen copolymers | |
EP1207917B1 (fr) | Materiau d'etancheite pour protheses vasculaires | |
KR20010038098A (ko) | 헤파린 처리된 항석회화성 생체조직 이식물 및 이의 제조 방법 | |
AU6908591A (en) | Hollow viscus prosthesis and method of implantation | |
Chandy et al. | Journal of Biomaterials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22912144 Country of ref document: EP Kind code of ref document: A2 |